Chronic Lower Back Pain Pipeline Analysis: 10+ Companies are Working to Improve the Treatment Space | DelveInsight

DelveInsight's, "Chronic Lower Back Pain Pipeline Insight, 2022," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Chronic Lower Back Pain pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key takeaways from the Chronic Lower Back Pain Pipeline Report
• DelveInsight's Chronic Lower Back Pain Pipeline report depicts a robust space with 10+ active players working to develop 10+ pipeline therapies for Chronic Lower Back Pain treatment.
• The leading Chronic Lower Back Pain Companies includes Mesoblast, Eli Lilly and Company, Persica Pharmaceuticals, CHABiotech, Allodynic Therapeutics, Stayble Therapeutics, Xgene Pharmaceutical, Imbrium Therapeutics, Camurus, and others are some of the key prominent pharma players working in the domain.
• The promising Chronic Lower Back Pain Therapies in the pipeline includes Bupivacaine TTS (Bupivacaine Patch), Duloxetine, AB001, Bicifadine, and others are under investigation in different phases of clinical trials for the treatment of Chronic Lower Back Pain.
• The companies and academics are working to assess challenges and seek opportunities that could influence Chronic Lower Back Pain R&D. The therapies under development are focused on novel approaches to treat/improve Chronic Lower Back Pain.

Get an overview of the Chronic Lower Back Pain Pipeline landscape @ https://www.delveinsight.com/sample-request/chronic-lower-back-pain-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Chronic Lower Back Pain Overview
Low back pain that has been present for longer than three months is considered as chronic, although there is still no consensus about the definition of Chronic Lower Back Pain (CLBP). 5-10% of all low back pain patients will develop CLBP. Chronic low back pain (CLBP) has been associated with neurochemical, structural, and functional cortical changes of several brain regions including the somatosensory cortex. Complex processes of peripheral and central sensitization may influence the evolution of acute to chronic pain. Most patients that suffer from CLBP experience pain in the lower area of the back (lumbar and sacroiliac regions) and mobility impairment. Diagnosis of low back pain is done on the basis of physical examination and patient history, sometimes followed by x-rays, CT scan, MRI, or other medical tests. Treatment for CLBP includes medications like acetaminophen (Tylenol), ibuprofen (Advil), and naproxen (Aleve). Physical therapy, occupational therapy, and lifestyle modification as well as other forms of exercise are also helpful.

Latest Breakthroughs in the Chronic Lower Back Pain Treatment Landscape
• MPC-06-ID is a tier 1 product candidate which consists of a unit dose of 6 million mesenchymal precursor cells (MPCs). It is injected by syringe directly into a targeted damaged disc in an outpatient procedure. MPC-06-ID is a Phase III product candidate for the treatment of chronic low back pain caused by disc degeneration (CLBP). It is being developed for patients who have exhausted conservative treatment options, may have failed epidural steroid injections and have no further treatment option other than invasive and costly surgical interventions.
• PP353 is a unique combination of an antibiotic, a radio-opaque dye and a thermosensitive gel that provides a product for intradiscal injection. It is currently being studied in Phase I/II developmental studies for the treatment of patients with Chronic Low Back Pain associated with verterbral body endplate bone oedema.

Chronic Lower Back Pain Emerging Drugs
• MPC-06-ID: Mesoblast
• PP353: Persica Pharmaceuticals
Get to know more information about Chronic Lower Back Pain treatment therapies @ https://www.delveinsight.com/sample-request/chronic-lower-back-pain-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Chronic Lower Back Pain Pipeline Therapeutics Analysis
There are approx. 10+ key companies which are developing the therapies for Chronic Lower Back Pain. The companies which have their Chronic Lower Back Pain drug candidates in the most advanced stage, i.e. Phase III include, Mesoblast.

DelveInsight's Chronic Lower Back Pain Pipeline Report covers around 10+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Discover more about therapy set to grab substantial Chronic Lower Back Pain Pipeline landscape @ https://www.delveinsight.com/report-store/chronic-lower-back-pain-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Chronic Lower Back Pain Pipeline Report
• Coverage- Global
• Chronic Lower Back Pain Companies- Mesoblast, Eli Lilly and Company, Persica Pharmaceuticals, CHABiotech, Allodynic Therapeutics, Stayble Therapeutics, Xgene Pharmaceutical, Imbrium Therapeutics, Camurus, and others.
• Chronic Lower Back Pain Therapies- Bupivacaine TTS (Bupivacaine Patch), Duloxetine, AB001, Bicifadine, and others
• Chronic Lower Back Pain Pipeline Assessment by Product Type
• Chronic Lower Back Pain Pipeline Assessment by Stage and Product Type
• Chronic Lower Back Pain Pipeline Assessment by Route of Administration
• Chronic Lower Back Pain Pipeline Assessment by Stage and Route of Administration
• Chronic Lower Back Pain Pipeline Assessment by Molecule Type
• Chronic Lower Back Pain Pipeline Assessment by Stage and Molecule Type

Table of Content
1. Introduction
2. Executive Summary
3. Chronic Lower Back Pain: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Chronic Lower Back Pain - DelveInsight's Analytical Perspective
7. In-depth Commercial Assessment
8. Chronic Lower Back Pain Collaboration Deals
9. Late Stage Products (Phase III)
10. MPC-06-ID: Mesoblast
11. Mid Stage Products (Phase II)
12. LY3016859: Eli Lilly and Company
13. Early Stage Products (Phase I/II)
14. PP353: Persica Pharmaceuticals
15. Preclinical and Discovery Stage Products
16. Drug name: Company name
17. Inactive Products
18. Chronic Lower Back Pain Key Companies
19. Chronic Lower Back Pain Key Products
20. Chronic Lower Back Pain- Unmet Needs
21. Chronic Lower Back Pain- Market Drivers and Barriers
22. Chronic Lower Back Pain- Future Perspectives and Conclusion
23. Chronic Lower Back Pain Analyst Views
24. Chronic Lower Back Pain Key Companies
25. Appendix

Got Queries? Reach out for more information on the Chronic Lower Back Pain Pipeline Report @ https://www.delveinsight.com/report-store/chronic-lower-back-pain-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Company Name: DelveInsight LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 09193216187
Address: 304 S. Jones Blvd #2432,
City: Las Vegas
State: United States
Country: India
Website: https://www.delveinsight.com/

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

This release was published on openPR.